Clinical Trial Update: A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of CDK-002 (exoSTING) in advanced/metastatic, recurrent injectable solid tumors completed phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CDK-002 (exoSTING) (CDK-002 (exoSTING))

Snippet

Sponsor: Codiak BioSciences | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED